Fig. 5

Oral administration with IRX4204 at peak disease (DPI 16) promotes remyelination in the lumbar spinal cord of EAE mice. (A and B) Representative electron microscopy images of the L3/L4 spinal cord region of EAE mice treated orally with vehicle (5 mL/kg/day; A) or IRX4204 (12 mg/kg/day; B). Arrows depict remyelinating axons. (C and D) Axonal counts revealed that remyelinating axons were more abundant (C) and made up a higher percentage of axons (D) in EAE mice following treatment with IRX4204 compared to EAE mice treated with vehicle starting at peak disease (n = 5, one-tailed Mann-Whitney U test, mean ± SEM; *p < 0.05)